Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121 (Suspension)
Drug: TEZ/IVA
Drug: Placebo (matched to VX-121 suspension)
Drug: Placebo (matched to TEZ/IVA)
Drug: VX-121 (Tablet)
Drug: Placebo (matched to IVA)
Drug: IVA
Drug: Placebo (matched to VX-121 tablet)

First Posted Date: 2018-12-07

Last Posted Date: 2022-07-14

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 115

Registration Number: NCT03768089

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱
HagaZiekenhuis van den Haag, Den Haag, Netherlands
🇳🇱
PRA Health Sciences Onderzoekscentrum UMCG, Groningen, Netherlands

and more 4 locations

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Phase 2

Completed

Conditions: Acute Pain

Interventions: Drug: VX-150
Drug: Placebo

First Posted Date: 2018-12-04

Last Posted Date: 2022-02-09

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 250

Registration Number: NCT03764072

Locations: 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Lotus Clinical Research, Pasadena, California, United States

and more 3 locations

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease
Hemoglobinopathies
Hematological Diseases

Interventions: Biological: CTX001

First Posted Date: 2018-11-19

Last Posted Date: 2024-10-31

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 63

Registration Number: NCT03745287

Locations: 🇺🇸
Lucile Packard Children's Hospital of Stanford University, Palo Alto, California, United States
🇺🇸
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago Hospitals and Health Systems, Chicago, Illinois, United States

and more 14 locations

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2018-10-02

Last Posted Date: 2021-10-22

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 71

Registration Number: NCT03691779

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 18 locations

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Phase 2

Active, not recruiting

Conditions: Thalassemia
Hemoglobinopathies
Hematologic Diseases
Beta-Thalassemia
Genetic Diseases, Inborn

Interventions: Biological: CTX001

First Posted Date: 2018-08-31

Last Posted Date: 2025-04-16

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 59

Registration Number: NCT03655678

Locations: 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Columbia University Medical Center (21+ years), New York, New York, United States

and more 11 locations

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Phase 3

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: VX-659/TEZ/IVA
Drug: IVA

First Posted Date: 2018-08-16

Last Posted Date: 2020-02-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 18

Registration Number: NCT03633526

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
The Children's Mercy Hospital, Kansas City, Missouri, United States

and more 3 locations

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: LUM/IVA

First Posted Date: 2018-08-10

Last Posted Date: 2022-11-02

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 51

Registration Number: NCT03625466

Locations: 🇩🇪
Charite Paediatric Pulmonology Department, Berlin, Germany
🇩🇪
Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin, Giessen, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: LUM
Drug: IVA

First Posted Date: 2018-07-26

Last Posted Date: 2023-01-06

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 61

Registration Number: NCT03601637

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Stanford University, Palo Alto, California, United States

and more 24 locations

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: TEZ/IVA
Drug: IVA

First Posted Date: 2018-06-15

Last Posted Date: 2020-02-11

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 67

Registration Number: NCT03559062

Locations: 🇦🇺
Hunter Medical Research Institute (HMRI), New Lambton Heights, Australia
🇦🇺
Princess Margaret Hospital for Children, Perth, Australia
🇦🇺
Lady Cilento Children's Hospital, South Brisbane, Australia

and more 24 locations

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: TEZ/IVA
Drug: IVA

First Posted Date: 2018-05-25

Last Posted Date: 2024-04-19

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 130

Registration Number: NCT03537651

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 52 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy